Elena Vendrame

Infectious Disease
965 High St
Palo Alto, CA 94301

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._.

Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._.

Journal: Communications medicine
Published: July 18, 2025

Combination immunotherapy induces post-intervention control of HIV.

Combination immunotherapy induces post-intervention control of HIV.

Journal: Research square
Published: April 01, 2025

Correlates of HIV-1 control after combination immunotherapy.

Correlates of HIV-1 control after combination immunotherapy.

Journal: Nature
Published: March 02, 2025

Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial.

Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial.

Journal: Nature communications
Published: October 31, 2024

Distinct immune profiles in children living with HIV based on timing and duration of suppressive antiretroviral treatment.

Distinct immune profiles in children living with HIV based on timing and duration of suppressive antiretroviral treatment.

Journal: Virology
Published: September 17, 2024

A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod.

A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod.

Journal: Infectious diseases and therapy
Published: July 12, 2024

Early Viral Dynamics Predict Human Immunodeficiency Virus Posttreatment Control After Analytic Treatment Interruption.

Early Viral Dynamics Predict Human Immunodeficiency Virus Posttreatment Control After Analytic Treatment Interruption.

Journal: The Journal of infectious diseases
Published: July 02, 2024

Circulating immune and plasma biomarkers of time to HIV rebound in HIV controllers treated with vesatolimod.

Circulating immune and plasma biomarkers of time to HIV rebound in HIV controllers treated with vesatolimod.

Journal: Frontiers in immunology
Published: March 22, 2024

HIV rebound in HIV controllers is associated with a specific fecal microbiome profile.

HIV rebound in HIV controllers is associated with a specific fecal microbiome profile.

Journal: European journal of immunology
Published: February 27, 2024

CyTOF analysis identifies unusual immune cells in urine of BCG-treated bladder cancer patients.

CyTOF analysis identifies unusual immune cells in urine of BCG-treated bladder cancer patients.

Journal: Frontiers in immunology
Published: June 16, 2022

Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients.

Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients.

Journal: Frontiers in cellular and infection microbiology
Published: August 12, 2021

The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy.

The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy.

Journal: Science translational medicine
Published: December 23, 2020
Showing 1-12 of 23

Last Updated: 09/26/2026